{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+product&page=5",
    "query": {
      "intervention": "Reference product",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 362,
    "total_pages": 37,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+product&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+product&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T05:20:41.528Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00853216",
      "title": "Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Oxycodone hydrochloride tablet 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Roxicodone™ tablet 30 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2003-01",
      "completion_date": "2003-02",
      "has_results": false,
      "last_update_posted_date": "2016-10-19",
      "last_synced_at": "2026-10-31T05:20:41.528Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00853216"
    },
    {
      "nct_id": "NCT00992329",
      "title": "Impact of Formulation on Ciprofloxacin Oral Absorption",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ciprofloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2013-01",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2020-11-06",
      "last_synced_at": "2026-10-31T05:20:41.528Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00992329"
    },
    {
      "nct_id": "NCT01247272",
      "title": "90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Fluoxetine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "PROZAC WEEKLY®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2001-05",
      "completion_date": "2001-07",
      "has_results": true,
      "last_update_posted_date": "2011-02-21",
      "last_synced_at": "2026-10-31T05:20:41.528Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01247272"
    },
    {
      "nct_id": "NCT04957992",
      "title": "BIG Study (Brain, Immune, and Gut Health Evaluation of Infants/Young Children Fed Infant Formula, and Later Supplemental Toddler Nutrition, With 5 Specific HMOs)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Growth"
      ],
      "interventions": [
        {
          "name": "Control Infant Formula",
          "type": "OTHER"
        },
        {
          "name": "Control Toddler Drink",
          "type": "OTHER"
        },
        {
          "name": "Experimental Infant Formula",
          "type": "OTHER"
        },
        {
          "name": "Experimental Toddler Drink",
          "type": "OTHER"
        },
        {
          "name": "Human Milk",
          "type": "OTHER"
        },
        {
          "name": "Human Milk Supplemental Formula",
          "type": "OTHER"
        },
        {
          "name": "Human Milk Toddler Drink",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Abbott Nutrition",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": "14 Days",
        "sex": "ALL",
        "summary": "0 Days to 14 Days"
      },
      "enrollment_count": 607,
      "start_date": "2021-07-21",
      "completion_date": "2025-05-12",
      "has_results": false,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-10-31T05:20:41.528Z",
      "location_count": 42,
      "location_summary": "Phoenix, Arizona • Glenwood, Arkansas • Hot Springs, Arkansas + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glenwood",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04957992"
    },
    {
      "nct_id": "NCT03541044",
      "title": "A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Healthy Smokers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tobacco Use Disorder"
      ],
      "interventions": [
        {
          "name": "Nicotine Prototype Mini lozenge",
          "type": "DRUG"
        },
        {
          "name": "Nicorette Mini Lozenge",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 46,
      "start_date": "2018-06-18",
      "completion_date": "2019-03-24",
      "has_results": true,
      "last_update_posted_date": "2020-03-12",
      "last_synced_at": "2026-10-31T05:20:41.528Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03541044"
    },
    {
      "nct_id": "NCT00931164",
      "title": "Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alternating Hemiplegia of Childhood"
      ],
      "interventions": [
        {
          "name": "Sodium Oxybate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "6 Months to 25 Years"
      },
      "enrollment_count": 6,
      "start_date": "2009-08",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2014-03-31",
      "last_synced_at": "2026-10-31T05:20:41.528Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00931164"
    },
    {
      "nct_id": "NCT03091777",
      "title": "Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bacterial Vaginosis"
      ],
      "interventions": [
        {
          "name": "GDC-229",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole Vaginal Gel 0.75%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Balmoral Medical company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 871,
      "start_date": "2017-03-10",
      "completion_date": "2018-03-27",
      "has_results": true,
      "last_update_posted_date": "2020-01-07",
      "last_synced_at": "2026-10-31T05:20:41.528Z",
      "location_count": 1,
      "location_summary": "Raleigh, North Carolina",
      "locations": [
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03091777"
    },
    {
      "nct_id": "NCT05674721",
      "title": "A Bioequivalence Study of Advil PM Liqui-Gels Minis (Ibuprofen/Diphenhydramine Hydrochloride 200 mg/25 mg) Compared to the Current Marketed Advil PM Liqui-Gels (Ibuprofen/Diphenhydramine Hydrochloride 200 mg/25 mg) in Healthy Adult Subjects Under Fasted Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Advil PM Liqui-Gels Minis",
          "type": "DRUG"
        },
        {
          "name": "Advil PM Liqui-Gels",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HALEON",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 77,
      "start_date": "2023-01-05",
      "completion_date": "2023-03-21",
      "has_results": true,
      "last_update_posted_date": "2024-08-23",
      "last_synced_at": "2026-10-31T05:20:41.528Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05674721"
    },
    {
      "nct_id": "NCT01751906",
      "title": "ABSORB III Randomized Controlled Trial (RCT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Coronary Artery Stenosis",
        "Coronary Disease",
        "Coronary Stenosis"
      ],
      "interventions": [
        {
          "name": "Absorb BVS",
          "type": "DEVICE"
        },
        {
          "name": "XIENCE",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2008,
      "start_date": "2012-12",
      "completion_date": "2020-10",
      "has_results": true,
      "last_update_posted_date": "2023-10-11",
      "last_synced_at": "2026-10-31T05:20:41.528Z",
      "location_count": 190,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01751906"
    },
    {
      "nct_id": "NCT03880357",
      "title": "To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Scalp Psoriasis"
      ],
      "interventions": [
        {
          "name": "Betamethasone Scalp Suspension 0.064%;0.0005%",
          "type": "DRUG"
        },
        {
          "name": "Taclonex®",
          "type": "DRUG"
        },
        {
          "name": "Placebo topical suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 485,
      "start_date": "2018-10-22",
      "completion_date": "2019-03-15",
      "has_results": false,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-10-31T05:20:41.528Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03880357"
    }
  ]
}